CPT Code 87624: High-Risk HPV DNA Test Billing Guide

Key takeaways

CPT 87624 reports high-risk HPV detection by nucleic acid (DNA or RNA), returned as one pooled result

It is a DNA-based test, so an order or report describing an HPV antigen or immunoassay does not support the code

Medicare requires G0476, not CPT 87624, for preventive HPV screening under its cervical cancer screening benefit

CPT 87621 was deleted on January 1, 2015; the current low-risk sibling code is CPT 87623

Pabau’s claims management software submits 87624 claims through Claim.MD and tracks the remittance that comes back

CPT code 87624 reports infectious agent detection by nucleic acid (DNA or RNA) for high-risk HPV types, returned as a single pooled result. It is a DNA-based test rather than an antigen or immunoassay test. Filing it against the wrong payer costs the entire reimbursement. Send 87624 to Medicare for a preventive screening encounter and the claim denies. No modifier will correct it, because Medicare requires G0476 for that benefit.

This guide covers the official descriptor and the rest of the nucleic acid HPV code family. It also covers the ICD-10-CM codes that pair with 87624, the fee schedule that prices it, co-testing rules, documentation, and the 2025 changes. Sexual health clinic and OB/GYN billing teams make the same routing decision on every cervical screening claim. For background on how laboratory claims move from encounter to payment, see the medical billing fundamentals guide.

CPT code 87624: official description and code details

CPT code 87624 describes infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types, pooled result. The descriptor lists the genotypes as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The American Medical Association (AMA) owns and maintains the CPT code set. According to the AMA’s CPT code set overview, codes in the 87000 series cover microbiology and infectious disease laboratory tests. Within that series, 87623 through 87626 are the nucleic acid HPV codes.

The pooled result is what separates 87624 from the rest of its family. The assay looks for the whole high-risk panel and returns one answer. If the laboratory reports individual genotypes, a different code applies. Billing 87624 against a genotyping report creates a specificity mismatch that payers flag on audit.

CPT 87624 vs G0476: which code to use for Medicare vs commercial payers

This is where most HPV billing errors start. CPT code 87624 and HCPCS G0476 describe the same clinical test, and they are not interchangeable. Medicare requires G0476 for preventive HPV screening under national coverage determination 210.2.1. Submitting CPT 87624 to Medicare for a preventive screening encounter produces a denial that no modifier will fix afterward.

The workflow is simple once it is written down. Verify the patient’s primary payer before the claim is built. If Medicare is primary, use G0476. If a commercial plan is primary, use CPT code 87624. Where a patient carries Medicare plus a secondary commercial plan, G0476 goes on the Medicare claim and the secondary claim follows it. Running insurance eligibility verification at scheduling catches this routing question before anyone builds a claim.

CPT 87623 vs CPT 87624: low-risk and high-risk HPV codes

Code choice follows what the laboratory reports, not what the ordering provider asked for. CPT 87623 covers low-risk HPV types. CPT 87624 covers the high-risk panel and returns a pooled result. Both are nucleic acid tests in the same CPT family, which is why the pair gets mixed up. Miscoding the distinction creates a medical necessity mismatch that clears initial adjudication and then surfaces on retrospective audit.

If a laboratory panel runs low-risk and high-risk typing at the same time, 87623 and 87624 may both be reportable, subject to the payer’s policy. Most cervical cancer screening protocols only need the high-risk test. Billing 87623 alone for a cervical cancer screening encounter draws a medical necessity denial, because low-risk types do not drive cervical cancer risk stratification. Read the genotype category off the laboratory report before you pick the code.

CPT 87621 is a deleted code

CPT 87621 is not a valid code, and has not been since January 1, 2015. It formerly read “Papillomavirus, human, amplified probe technique,” which named the assay method rather than a risk category. The 2015 CPT set retired that technique-based family and replaced it with the risk-stratified codes 87623, 87624, and 87625. Any billing template, order set, or internal crosswalk still holding 87621 will reject, so the low-risk comparison to make is 87623 against 87624.

ICD-10-CM diagnosis codes for CPT 87624

Every CPT 87624 claim needs a covered ICD-10-CM diagnosis code. Submitting the code with no valid linked diagnosis produces an automatic denial from any payer. The diagnosis has to reflect the clinical reason for the test rather than the result. According to the CDC/NCHS ICD-10-CM tool, codes are reported at their highest level of specificity for each encounter.

Z12.4 is the usual pairing for routine co-testing. When HPV testing follows an abnormal Pap, the cytology finding code drives the claim, and Z12.4 may follow as an additional code. Do not report Z11.51 and Z12.4 together on the same claim, since payers generally accept one screening indicator per visit.

Three ICD-10-CM traps on HPV claims

• R87.82 is not a high-risk code. It is the low-risk parent, “low risk human papillomavirus (HPV) DNA test positive,” and it is not billable at that level of detail. Report R87.820 for a cervical low-risk positive, which belongs with 87623 rather than 87624.
• R87.81 is the high-risk parent, and it is also non-billable. Use R87.810 for a cervical high-risk HPV DNA positive result, or R87.811 for a vaginal one.
• HSIL is a cytology finding, not an HPV result. It sits in the R87.61- series, where R87.613 reports HGSIL on a cervical smear. R87.810 reports a positive high-risk HPV DNA test. The two codes answer different questions and are not interchangeable.

Medicare screening claims carry their own pairing rule. The Medicare Administrative Contractor articles for cervical cancer screening with HPV set the pairing for G0476. Report Z11.51 as the primary diagnosis, plus Z01.411 or Z01.419 as a secondary code. State Medicaid programs publish their own accepted crosswalks, so check the current list in the provider manual before filing.

Medicare coverage and frequency limitations for CPT 87624

Medicare does not pay CPT code 87624 for preventive HPV screening. Those claims go out with G0476. CPT 87624 stays billable to Medicare only when the test is ordered for a diagnostic reason, such as follow-up after abnormal cytology. Coverage turns on whether the encounter is preventive or diagnostic, and the two paths have different cost-sharing rules.

• Preventive screening (use G0476): asymptomatic female beneficiaries aged 30 to 65, once every 5 years, as an all-inclusive HPV co-test with cytology under NCD 210.2.1.
• Diagnostic indication (CPT 87624 may apply): reflex testing after an ASC-US Pap result, follow-up of known HPV-positive status, or work-up of abnormal cytology. Standard deductible and coinsurance apply.
• Screening cytology runs on its own clock: Medicare covers a screening Pap every 24 months, and annually for beneficiaries at high risk. That interval is separate from the 5-year HPV co-test interval.
• Frequency edits: billing a screening HPV test inside the covered interval without a diagnostic indication triggers a denial. An advance beneficiary notice lets the practice bill the patient when she agrees to pay.
• CLIA requirement: the performing laboratory must hold a CLIA certificate. When the specimen goes to a reference laboratory, the claim carries that laboratory’s NPI as well as the ordering provider’s.

Practices billing Medicare should confirm the coverage criteria before scheduling preventive HPV testing. Billing 87624 where G0476 is required is a recoverable audit finding. Build the check into the medical billing compliance routine rather than leaving it to individual billers.

CPT code 87624 reimbursement and payment basis

CPT 87624 is paid under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. That one fact answers several questions at once. There are no relative value units for this code, no facility versus non-facility split, and no geographic practice cost adjustment. CMS publishes a single national payment amount per laboratory code and updates it under the PAMA private payor rate methodology.

Rate aggregator sites and Physician Fee Schedule lookups are the wrong tools for this code. The MPFS search returns nothing usable for 87624, which is why some practices conclude the code is unpriced. Pull the figure from the current-year CLFS file instead, and compare it against each contracted commercial rate.

Pabau’s claims management software submits 87624 claims electronically through Claim.MD. Its built-in CPT and ICD-10-CM catalogues give staff a maintained list to select codes from as they build the claim. Electronic remittance advice returns through the same integration. Each payment posts against the claim it settles, so you can see the paid amount next to the expected one.

Billing CPT 87624 with a Pap smear: co-testing rules and NCCI edits

Co-testing means collecting a Pap smear and an HPV test at the same encounter. It is the most common clinical scenario for CPT code 87624. Billing both codes together is appropriate and expected when both tests are performed. NCCI bundling edits govern which code combinations are allowed without a modifier.

Common Pap smear codes paired with 87624

• 88175 (cytopathology, cervical or vaginal, automated thin layer preparation, screening by automated system with manual rescreening or review) – the most frequently billed co-testing pair
• 88174 (cytopathology, cervical or vaginal, automated thin layer preparation, screening by automated system under physician supervision) – the alternate liquid-based code
• 88164 through 88166 (Papanicolaou smear, cervical or vaginal, Bethesda System) – conventional smear codes, now uncommon in liquid-based workflows

NCCI bundling rules for CPT 87624

The National Correct Coding Initiative (NCCI) edits define which code pairs cannot be billed together without a modifier. Edits are updated quarterly, so check the current CMS table rather than a prior-year copy saved in a billing folder.

• Where an edit exists between 87624 and a paired Pap code, modifier 59 is the standard override. Use it only when the tests are genuinely separate and independently ordered
• Modifier 91 applies when the same laboratory test is repeated on the same day for a medically necessary reason
• Modifier QW applies in CLIA-waived settings, though 87624 is normally performed in high-complexity laboratories
• Never append modifier 59 purely to clear an edit. The chart note has to support the separate medical necessity of each test

A clean claim submission checklist for 87624 co-testing confirms three things. Both the cytology and HPV codes are present, the modifier is justified in the chart note, and the ICD-10-CM code supports both tests. The superbill documentation should record the indication for the Pap and the indication for the HPV test separately.

Documentation requirements for CPT 87624 claims

Documentation is the second most common denial driver after wrong payer code selection. The chart note has to support medical necessity for the HPV test on its own, independently of anything else billed at the same encounter.

• Clinical indication: the note states why the HPV test was ordered. For routine screening, record age, screening interval, and last test date. For reflex testing, record the cytology result that triggered the order.
• Test performed: the order and the laboratory report should show a high-risk HPV nucleic acid test with a pooled result. Low-risk panels and genotyping reports map to different CPT codes.
• Ordering provider: the ordering NPI has to appear on the claim. For reference laboratory specimens, include both the ordering and the performing NPI in the right claim fields.
• Specimen source: a cervical specimen is implied for cervical cancer screening, but state it explicitly on the laboratory requisition and in the report.
• ICD-10-CM linkage: the diagnosis has to be linked to 87624 in the service-line diagnosis pointer fields. A code listed in box 21 with no pointer will not hold up.
• Patient acknowledgment: some plans want documentation that the patient was told the test is part of a preventive screening protocol. Check the specific benefit structure.

2025 HPV coding updates affecting CPT 87624

The 2025 changes landed in the CPT code set rather than in the coverage rules. One new code arrived, and the descriptors around it were tightened so that pooled results and genotyping stopped competing for the same code.

• CPT 87626 is new for 2025. It reports separately identified high-risk types together with the high-risk pooled result from a single analysis, and it replaced Category III code 0500T. Do not report it with 87624 or 87625 for the same procedure.
• 87624 remains the pooled-result code. The “pooled result” wording keeps it distinct from the genotyping reported under 87625 and the combined reporting now covered by 87626.
• G0476 is unchanged for Medicare preventive screening. The MAC billing and coding articles still call for Z11.51 as primary with Z01.411 or Z01.419. CPT 87624 is not a substitute on a preventive claim.
• State Medicaid crosswalks move on their own schedule. Medi-Cal and other state programs publish the diagnosis codes they accept on HPV claims in their provider manuals. Verify the list annually, because a code accepted last year may not map this year.
• ICD-10-CM fiscal year updates land every October 1. Review the tabular list on the CMS ICD-10 codes page to confirm the crosswalk codes in your billing system are still valid.
• Commercial policies track cervical screening guidance. Age and frequency criteria shift between plan years, so re-verify each payer rather than assuming last year’s policy holds.

An annual crosswalk validation step every January catches these changes before they turn into batch denials in the first quarter. Build it into the claims clearinghouse workflow as a scheduled task, with a named owner, rather than leaving it to whoever notices the first rejection.

Common billing errors and denial reasons for CPT 87624

Most CPT 87624 denials fall into five categories, and each one has a specific root cause and a defined fix. Tracking denials by category rather than one claim at a time is the fastest way to bring the rate down across a full screening caseload.

A workable denial management routine for HPV claims has three parts. Run a monthly denial category report, check the 87624 and Pap code pairing before submission, and verify the payer at scheduling for every Medicare patient. Grouping denials by claim adjustment reason code is the quickest way to tell a systemic workflow problem from a one-off error. The denial codes reference explains what each code means.

Prior authorization requirements for CPT 87624

Prior authorization for CPT code 87624 varies by payer and plan year, and no universal rule applies. For routine preventive cervical cancer screening inside recommended intervals, most major commercial payers do not require it. The ACA generally covers preventive services without pre-approval. Testing outside standard intervals or age parameters is where authorization requirements start to appear.

• Aetna: preventive HPV testing within age and frequency guidelines is typically covered without prior authorization. Diagnostic or high-frequency testing may go to clinical review.
• Blue Cross Blue Shield: requirements vary by regional plan. Verify the specific patient’s plan through the provider portal or member services.
• Anthem / Elevance Health: authorization is generally not required for routine preventive screening. Verify it for extended high-risk testing panels.
• Cigna: routine preventive HPV testing is covered without authorization at eligible ages and frequencies. Additional testing may need prior review.
• Medicare: no prior authorization for the G0476 preventive benefit inside the covered interval, and none for diagnostic use of 87624.

Verify current requirements with the payer before performing the test for any non-routine indication. These policies change annually, and sometimes mid-year. State Medicaid programs, Medi-Cal included, publish their authorization rules in their provider manuals, and those should be reviewed separately from commercial policies.

How Pabau supports CPT 87624 claim submission and tracking

On an HPV claim the coding decision takes seconds, and the consequence shows up weeks later. A biller checks the payer, picks 87624 or G0476, links the diagnosis, and sends the claim. If the routing was wrong, the practice learns about it from a remittance advice a month afterward. By then the encounter is cold and the rework costs more than the claim.

Practice management software like Pabau keeps that chain in one place. Charges built at checkout carry through into the claim. Built-in CPT and ICD-10-CM catalogues give staff a maintained list to select codes from instead of typing them off a printout. Pabau’s claims management then submits the claim electronically through Claim.MD and tracks its status from there.

Remittance advice comes back through the same integration, so payments and adjustments post against the claim they settle. Denials collect in one queue rather than a shared inbox, which is what makes a monthly denial-by-category review practical. Pabau submits and tracks what your records hold, and the coding judgment stays with your billers. Keep the payer check and the crosswalk review in your own workflow.

Submit and track HPV screening claims in one place

Pabau’s claims management submits CPT 87624 and G0476 claims electronically through Claim.MD. Every remittance returns to the same queue, so denials surface where your billers already work.

Book a demo

Conclusion

The expensive 87624 errors are the ones that look like details. The descriptor names a nucleic acid test, so an order documenting an HPV immunoassay does not support the code. CPT 87621 has been dead since 2015, so a crosswalk still holding it will reject. R87.82 is a low-risk parent code rather than a high-risk one. None of these are judgment calls, which is exactly why they are worth correcting once at the template level.

The routing decision deserves a control of its own. Verify the primary payer before the claim is built, use G0476 when Medicare is primary, and keep the diagnosis pointer linked at the service line. That combination clears most 87624 denials before a payer ever sees the claim.

Pabau’s claims management software submits 87624 and G0476 claims through Claim.MD and tracks each remittance against the claim it settles. Book a demo to see how it handles cervical cancer screening billing end to end.

Continue your research

Need a framework for managing claim denials systematically? Denial management in healthcare walks through how to categorize, track, and resolve ERA adjustment reasons across high-volume billing workflows.

Want to understand how clearinghouse submissions work end to end? Medical claims clearinghouse workflow explains how electronic claims move from practice management system to payer and back.

Billing IVF or reproductive health lab panels alongside cervical screening? IVF CPT codes for reproductive health billing covers the lab code families that frequently co-occur with HPV testing in OB/GYN and fertility clinic workflows.

Frequently asked questions